Current status of the iron hypothesis of cardiovascular diseases;La cosiddetta "iron hypothesis": Un persistente stato di deplezione di ferro può proteggere contro le malattie cardiovascolari?

Recenti Progressi in Medicina

Volumn 98, Issue 7-8, 2007, Pages 373-377

  Sullivan, Jerome L ^a,c   Mascitelli, Luca ^b  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b Servizio Sanitario   (Italy)

^c NONE   (United States)

Author keywords

Cardiovascular diseases; Ferritin; Hepcidin; Iron

Indexed keywords

IRON;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HEART PROTECTION; HUMAN; IRON CHELATION; IRON DEFICIENCY; IRON DEPLETION; IRON RESTRICTION; MORTALITY; PHLEBOTOMY; REVIEW;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FERRITINS; HEMOCHROMATOSIS; HUMANS; IRON; MACROPHAGES; MYOCARDIAL ISCHEMIA; PHLEBOTOMY; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SEX FACTORS;

EID: 34250882313     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1: 1293-4.
2. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J 1989; 117: 1177-88.
3. Sullivan JL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J 2003; 145: 190-4.
4. Sullivan JL. Stored iron and vascular reactivity. Arterioscler Thromb Vasc Biol 2005; 25: 1532-5.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
6. Mascitelli L, Pezzetta F. Cardiovascular protection in premenopausal women. Arch Intern Med 2005; 165: 120.
7. Sullivan JL. Estrogen and heart disease: alternatives to a paradigm in crisis. Arch Intern Med 2006; 166: 2160.
8. Sullivan JL. Is homocysteine an iron-dependent cardiovascular risk factor? Kidney Int 2006; 69: 642-4.
9. Zheng H, Huang X, Zhang Q, Katz SD. Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int 2006; 69: 679-84.
10. Zheng H, Dimayuga C, Hudaihed A, Katz SD. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterioscler Thromb Vasc Biol 2002; 22: E15-8.
11. Suh JR, Oppenheim EW, Girgis S, Stover PJ. Purification and properties of a folate-catabolizing enzyme. J Biol Chem 2000; 275: 35646-55.
12. Boers GH, Smals AG, Trijbels FJ, Leermakers AI, Kloppenborg PW. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983; 72: 1971-6.
13. Sullivan JL. Is stored iron safe? J Lab Clin Med 2004; 144: 280-4.
14. Sullivan JL. Macrophage iron, hepcidin and atherosclerotic plaque stability. Exp Biol Med (in corso di pubblicazione).
15. Yuan XM. Apoptotic macrophage-derived foam cells of human atheromas are rich in iron and ferritin, suggesting iron-catalysed reactions to be involved in apoptosis. Free Radic Res 1999; 30: 221-31.
16. Minqin R, Rajendran R, Pan N, Kwong-Huat Tan B, Ong WY, Watt F, et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radical Biology and Medicine 2005; 38: 1206-11.
17. Lee HT, Chiu LL, Lee TS, Tsai HL, Chau LY. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J Biomed Sci 2003; 10: 510-7.
18. Stanley N, Stadler N, Woods AA, Bannon PG, Davies MJ. Concentrations of iron correlate with the extent of protein, but not lipid, oxidation in advanced human atherosclerotic lesions. Free Radical Biology and Medicine 2006; 40: 1636-43.
19. Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 1999; 99:1222-9.
20. Watt F, Rajendran R, Ren MQ, Tan BKH, Halliwell B. A nuclear microscopy study of trace elements Ca, Fe, Zn and Cu in atherosclerosis. Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 2006; 249: 646-52.
21. Lee HT, Chiu LL, Lee TS, Tsai HL, Chau LY. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J Biomed Sci 2003; 10: 510-7.
22. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Reduction of iron stores and cardiovascular outcomes in patients with pe-ripheral arterial disease: a randomized controlled trial. JAMA 2007; 297: 603-10.
23. Zacharski LR, Chow B, Howes PS, Lavori PW, Shamayeva G, Baron JA, et al. Effect of reduction of iron (Fe) stores on cardiovascular and cancer outcomes in patients with Advanced Peripheral Arterial Disease (PAD): VA Cooperative Study #410, the Iron (Fe) and Atherosclerosis Study (FeAST). Abstract #1807. Blood 108[11], 512a-513a. 11-16-2006.
24. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164: 1427-36.
25. Mascitelli L, Pezzetta F. Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer. J Intern Med 2006; 260: 592-3.
26. Mascitelli L, Pezzetta F. Questioning the "beatification" of statins. Int J Cardiol 2007, Feb 21 (Epub ahead of print).
27. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007; 115: 27-33.
28. Yuan XM, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann Med 2003; 35: 578-91.
29. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr., et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001; 103: 2799-804.
30. de Valk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999; 159: 1542-8.
31. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssonen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol 1998; 148: 445-51.
32. Lee DH, Zacharski LR, Jacobs J. Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes. American Heart Journal 2006; 151:1247.
33. Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 2002; 967:342-351.
34. Zheng H, Cable R, Spencer B, Votto N, Katz SD. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol 2005; 25: 1577-83.
35. Zamboni P. The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006; 99: 589-93.
36. Lapenna D, Pierdomenico SD, Ciofani G, Ucchino S, Neri M, Giamberardino MA, et al. Association of body iron stores with low molecular weight iron and oxidant damage of human atherosclerotic plaques. Free Radic Biol Med 2007; 42: 492-8.
37. Mascitelli L, Pezzetta F. Cardiovascular protections in severely impaired hemostasis. Circulation 2004; 110:e39.